PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 25, 20260 citationsOpen Access

Malaria research and its influence on anti-malarial drug policy in Malawi: a case study

View Full Paper
HCHuman Sciences Research Council

Key Points

  • To evaluate the justification and evidence supporting anti-malarial policy changes in Malawi.
  • Examined historical data on anti-malarial drug changes from chloroquine to sulfadoxine-pyrimethamine and then to lumefantrine-artemether
  • Analyzed the implications of these changes on drug resistance and treatment efficacy.
  • The 1993 policy change raised concerns about timely implementation and potential resistance development to sulfadoxine-pyrimethamine.
  • Evidence suggests changing drug policies may have influenced the resistance patterns of Plasmodium falciparum in Malawi.

Abstract

In 1993, Malawi changed its first-line anti-malarial treatment for uncomplicated malaria from chloroquine to sulfadoxine-pyrimethamine (SP), and in 2007, it changed from SP to lumefantrine-artemether. The change in 1993 raised concerns about whether it had occurred timely and whether it had potentially led to early development of Plasmodium falciparum resistance to SP. This case study examined evidence from Malawi in order to assess if the policy changes were justifiable and supported by evidence.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Human Sciences Research Council (2026) studied this question.

synapsesocial.com/papers/6a13e7cf0e02ee3982d3266ahttps://doi.org/10.14749/32384724
Ask AI
Helpful
Bookmark
Share
View Full Paper